8952 Schlieren, ch
+41 (44) 73347-47
Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure
The Authorized Share Capital shall be increased and adapted from currently 1'592'246 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.
The Conditional Share Capital for Bonds or Similar Debt Instruments shall be increased from cur-rently 1'720'585 to 4'000'000 registered shares with a nominal value of CHF 1.00 each.
The Conditional Share Capital for Employees, Persons of Comparable Positions and Board Mem-bers shall be increased from currently 1'389'647 to 2'248'389 registered shares with a nominal value of CHF 1.00 each
Documents for the EGM, including the Information Notice with a full agenda, will be made availa-ble online on June 26th at: http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_e_2019.pdf
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.